Objective To investigate the value of repeat renal biopsy in the treatment and prognosis of nephrotic syndrome(NS)and acute kidney injury(AKI)following immunosuppressive therapy in patients with lupus nephritis(LN).Methods A retrospective analysis was conducted for the clinicopathological data and follow-up records of LN patients undergoing repeat renal biopsy at Peking Union Medical College Hospital from January 1,2009 to December 31,2021.Results A total of 76 patients(55 females,72.4%)were included in this study,with the mean age at the first biopsy being(29.0±10.4)years,the median inter-biopsy interval of4.0(2.0,7.0) years,and the median total follow-up duration of 7.5(5.0,13.8)years.Pathological transformation occurred in 46(60.5%)patients,and 2 patients had comorbid diabetic nephropathy.At repeat renal biopsy,50(65.8%) patients presented NS.These patients demonstrated lower estimated glomerular filtration rate(eGFR)(P<0.001),higher chronicity index(CI)(P=0.029),and higher complement C3(P<0.001)and C4(P<0.001)levels than those with NS at the first renal biopsy(n=50).Among the 28(36.8%) patients with AKI at repeat renal biopsy,8(28.6%)experienced acute exacerbation of chronic renal insufficiency.These patients exhibited higher serum creatinine level(P=0.002),C4 level(P=0.033),CI(P=0.042),and prevalence of thrombotic microangiopathy(P=0.046)than the patients showing AKI at the first renal biopsy(n=16),while the activity index(AI)showed no significant difference(P=0.051).Over 50% of NS and AKI patients underwent treatment modifications post-repeat renal biopsy,with clinical remission rates comparable to those after the first renal biopsy(both P>0.05).Elevated CI(≥5,P=0.001)and serum creatinine(≥140 μmol/L,P<0.001)at repeat renal biopsy were identified as independent risk factors for poor prognosis.The patients with AKI at repeat renal biopsy had higher incidence of endpoint events than the non-AKI patients(P=0.015).Neither AKI at the first renal biopsy nor NS at both biopsies had significant associations with prognosis.Conclusions Repeat renal biopsy reveals not only sustained high disease activity but also accelerates chronic progression in LN patients,which underscore its critical role in guiding the therapy for severe LN post-immunosuppression.AKI,CI≥5,and serum creatinine ≥140 μmol/L at repeat renal biopsy are strongly associated with poor prognosis.
Key words
repeat renal biopsy /
lupus nephritis /
nephrotic syndrome /
acute kidney injury
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Greloni G,Scolnik M,Marin J,et al.Value of repeat biopsy in lupus nephritis flares[J].Lupus Sci Med,2014,1(1):e000004.DOI:10.1136/lupus-2013-000004.
[2] Palevsky PM,Liu KD,Brophy PD,et al.KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury[J].Am J Kidney Dis,2013,61(5):649-672.DOI:10.1053/j.ajkd.2013.02.349.
[3] Kidney Disease:Improving Global Outcomes(KDIGO) Glomerular Diseases Work Group.KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases[J].Kidney Int,2021,100(4S):S1-S276.DOI:10.1016/j.kint.2021.05.021.
[4] Kellum JA,Sileanu FE,Bihorac A,et al.Recovery after acute kidney injury[J].Am J Respir Crit Care Med,2017,195(6):784-791.DOI:10.1164/rccm.201604-0799OC.
[5] Weening JJ,D'Agati VD,Schwartz MM,et al.The classification of glomerulonephritis in systemic lupus erythematosus revisited[J].Kidney Int,2004,65(2):521-530.DOI:10.1111/j.1523-1755.2004.00443.x.
[6] Bajema IM,Wilhelmus S,Alpers CE,et al.Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis:clarification of definitions,and modified National Institutes of Health activity and chronicity indices[J].Kidney Int,2018,93(4):789-796.DOI:10.1016/j.kint.2017.11.023.
[7] Wang GB,Xu ZJ,Liu HF,et al.Changes in pathological pattern and treatment regimens based on repeat renal biopsy in lupus nephritis[J].Chin Med J(Engl),2012,125(16):2890-2894.DOI:10.3760/cma.j.issn.0366-6999.2012.16.017.
[8] Gasparotto M,Gatto M,Binda V,et al.Lupus nephritis:clinical presentations and outcomes in the 21st century[J].Rheumatology(Oxford),2020,59(Suppl5):v39-v51.DOI:10.1093/rheumatology/keaa381.
[9] Parodis I,Tamirou F,Houssiau FA.Treat-to-target in lupus nephritis.What is the role of the repeat kidney biopsy[J].Arch Immunol Ther Exp(Warsz),2022,70(1):8.DOI:10.1007/s00005-022-00646-9.
[10] De Rosa M,Azzato F,Toblli JE,et al.A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy[J].Kidney Int,2018,94(4):788-794.DOI:10.1016/j.kint.2018.05.021
[11] Narváez J,Ricse M,Gomà M,et al.The value of repeat biopsy in lupus nephritis flares[J].Medicine(Baltimore),2017,96(24):e7099.DOI:10.1097/MD.0000000000007099.
[12] Arriens C,Chen S,Karp DR,et al.Prognostic significance of repeat biopsy in lupus nephritis:histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death[J].Clin Immunol,2017,185:3-9.DOI:10.1016/j.clim.2016.11.019.
[13] Gupta KL,Bharati J,Anakutti H,et al.Contribution of clinically indicated repeat renal biopsy in Indian patients with lupus nephritis[J].Indian J Nephrol,2020,30(6):377-381.DOI:10.4103/ijn.IJN_166_19.
[14] Moroni G,Depetri F,Ponticelli C.Lupus nephritis:when and how often to biopsy and what does it mean[J].J Autoimmun,2016,74:27-40.DOI:10.1016/j.jaut.2016.06.006.
[15] Moroni G,Porata G,Raffiotta F,et al.Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis[J].Lupus Sci Med,2022,9(1):e000721.DOI:10.1136/lupus-2022-000721.
[16] Parodis I,Adamichou C,Aydin S,et al.Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis[J].Rheumatology(Oxford,England),2020,59(11):3424-3434.DOI:10.1093/rheumatology/keaa129.
[17] Morales E,Trujillo H,Bada T,et al.What is the value of repeat kidney biopsies in patients with lupus nephritis[J].Lupus,2021,30(1):25-34.DOI:10.1177/0961203320965703.
[18] Leatherwood C,Speyer CB,Feldman CH,et al.Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy(IFTA)and vascular injury in lupus nephritis biopsies[J].Semin Arthritis Rheum,2019,49(3):396-404.DOI:10.1016/j.semarthrit.2019.06.002.
[19] Pakozdi A,Pyne D,Sheaff M,et al.Utility of a repeat renal biopsy in lupus nephritis:a single centre experience[J].Nephrol Dial Transplant,2018,33(3):507-513.DOI:10.1093/ndt/gfx019.
[20] Aringer M,Costenbader K,Daikh D,et al.2019 European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus[J].Ann Rheum Dis,2019,78(9):1151-1159.DOI:10.1136/annrheumdis-2018-214819.
[21] Gandino IJ,Scolnik M,Bertiller E,et al.Complement levels and risk of organ involvement in patients with systemic lupus erythematosus[J].Lupus Sci Med,2017,4(1):e000209.DOI:10.1136/lupus-2017-000209.
[22] Alsuwaida A,Husain S,Al Ghonaim M,et al.Prognostic significance of C1q deposition in serial biopsies for predicating the long-term outcome in patients with proliferative lupus nephritis[J].Saudi J Kidney Dis Transpl,2016,27(2):305-311.DOI:10.4103/1319-2442.178547.
